Company intelligence / Profile preview

Max Zeller Söhne

Romanshorn, Thurgau, Switzerlandzellerag.ch ↗

Ownership: Private
Employees: ~145
Development stage: Other

Overview

Max Zeller Söhne is a Swiss market leader in clinically proven phytopharmaceuticals. The company controls the entire value chain from seed to finished product and has published preclinical and clinical studies supporting its products' efficacy. Its portfolio includes several well-established herbal medicines for women's health, CNS conditions, and allergies. Products are marketed in Switzerland and over 30 countries worldwide.

Therapeutic areas: ImmunologyNeurologyWomen's Health
Modalities: Herbal medicinePhytopharmaceuticals (plant-based medicines)Small molecule
Industry: Biotech

Drug pipeline

10 assets

St. John's wort extract Ze 117

9 more assets in the full pipeline.

Request access →

Partnerships

Not specifically listed; collaborates with Vitaplant for raw materials.

Beyond the preview

Go deeper on Max Zeller Söhne.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Max Zeller Söhne.

Explore the full profile